Effect of Metformin on Decrement in Levothyroxin Dose Required for Thyroid Stimulating Hormone (TSH) Suppression in Patients With Differentiated Thyroid Cancer

Differentiated thyroid cancer is the most common neoplasm of endocrine system. After surgery and radioiodine treatment, thyroid stimulating hormone (TSH) suppression is the main goal which is achieved with levothyroxine treatment. Levothyroxine causes increased thyroid hormones which can have negative impact on bone and cardiovascular system. Anecdotal reports have shown that metformin can induce TSH suppression without change in T3 and T4 concentration. The purpose of this study was to prescribe metformin as additional drug to levothyroxin in order to decrease levothyroxine dosage.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Malignant Neoplasm of Thyroid Stage I Endocrine Gland Neoplasms Endocrine System Diseases Head and Neck Neoplasms Malignant Neoplasm of Thyroid Stage II Neoplasms Neoplasms by Site Thyroid Diseases Thyroid Neoplasms

Age range

Up to 80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mashad University of Medical Sciences

Mashhad, Razavi Khorasan Province, Iran

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

papillary or follicular thyroid cancer
stage 1 or 2 according to TNM system version 6
surgery and radioiodine treatment
levothyroxine suppression treatment

Exclusion criteria

cardiopulmonary failure
liver failure
renal failure
pregnancy
drugs (colestyramin, sucralfate, phenobarbital, phenytoin, carbamazepin, rifampin, amiodarone, chloroquin, androgens, sertraline, frusemide, heparin)

Treatment and study plan

metformin

Drug

in case group metformin is added to levothyroxine and levothyroxine is decreased by 30% .in control group levothyroxine is reduced by 30% and no metformin is added to the regimen.

Primary outcomes

TSH

Time frame: 3 months

Secondary outcomes

freeT3,freeT4

Time frame: 3months

Sponsors and collaborators

Lead sponsor

Mashhad University of Medical Sciences

Other

Registry information

Important dates

Study start: 2010
Primary completion: 2011
Study completion: 2011
First posted: Apr 26, 2011
Registry last updated: Apr 26, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed